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Abstract
Background: Human breast cancer is classified by gene expression profile into subtypes consisting of two
hormone (oestrogen and/or progesterone) receptor-positive types (luminal-like A and luminal-like B) and three
hormone receptor-negative types [human epidermal growth factor receptor 2-expressing, basal-like, and
unclassified ("normal-like”)]. Immunohistochemical surrogate panels are also proposed to potentially identify the
molecular-based groups. The present study aimed to apply an immunohistochemical panel (anti-ER, -PR, -ERB-B2,
-CK 5/6 and -CK14) in a series of canine malignant mammary tumours to verify the molecular-based classification,
its correlation with invasion and grade, and its use as a prognostic aid in veterinary practice.
Results: Thirty-five tumours with luminal pattern (ER+ and PR+) were subgrouped into 13 A type and 22 B type, if
ERB-B2 positive or negative. Most luminal-like A and basal-like tumours were grade 1 carcinomas, while the
percentage of luminal B tumours was higher in grades 2 and 3 (Pearson Chi-square P = 0.009). No difference in
the percentage of molecular subtypes was found between simple and complex/mixed carcinomas (Pearson Chi-
square P = 0.47). No significant results were obtained by survival analysis, even if basal-like tumours had a more
favourable prognosis than luminal-like lesions.
Conclusion: The panel of antibodies identified only three tumour groups (luminal-like A and B, and basal-like) in
the dog. Even though canine mammary tumours may be a model of human breast cancer, the existence of the
same carcinoma molecular subtypes in women awaits confirmation. Canine mammary carcinomas show high
molecular heterogeneity, which would benefit from a classification based on molecular differences. Stage and
grade showed independent associations with survival in the multivariate regression, while molecular subtype
grouping and histological type did not show associations. This suggests that caution should be used when
applying this classification to the dog, in which invasion and grade supply the most important prognostic
information.
Background
Human breast cancer is considered a heterogeneous dis-
ease, and is classified by gene expression profile into
subtypes consisting of two hormone (oestrogen and/or
progesterone) receptor-positive types (luminal-like A
and luminal-like B) and three hormone receptor-nega-
tive types [human epidermal growth factor receptor 2-
expressing, basal-like, and unclassified ("normal-like”)]
[1-3]. Epidermal growth factor receptor 2 is indicated in
different ways in the literature, namely HER2, c-ERB-2,
neu, ERB-B2. This study uses the acronym ERB-B2. Fol-
low-up studies have shown these subtypes to be con-
served across diverse patient series and array platforms
[4,5], and that different gene expression-based predictors
are likely tracking a similar common set of biological
subtypes, with significant agreement in predicting
patients’ clinical outcome [6].
Cost and complexity issues have to date rendered gene
expression profiling impractical in laboratories equipped
for routine diagnostic tests. However, some of the
immunohistochemistry surrogate panels proposed can
potentially identify the molecular-based groups
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any medium, provided the original work is properly cited.according to classification flowcharts [7] (figure 1). The
panels encompass at least anti-oestrogen receptor (ER),
anti-progesterone receptor (PR), anti-ERB-B2 and anti-
basal cytokeratin antibodies (CK 5/6 and 14) [8,9].
Basal-like breast cancers are characterized by the lack of
ER, PR and ERB-B2 expression and cytokeratin 5/6 and/
or epidermal growth factor receptor expression [7],
whereas the luminal-like subtype is characterized by ER
or PR expression [7] and further subgrouped into lumi-
nal A or B depending on the absence or presence of
ERB-B2 expression [10]. Negativity for luminal biomar-
kers, positivity or negativity for basal markers and ERB-
B2 positivity characterizes the ERB-B2 overexpressing
group [10].
Canine mammary tumours are considered a sponta-
neous animal model of human breast cancer [11,12]
prevalently on a histomorphological basis, but several
differences between the tumours of the two species
must be taken into account to make any comparisons
feasible. Myoepithelial cell proliferation is a frequent
finding in the so-called complex and mixed patterns
[13,14], but it is an uncommon feature of breast cancer
in women [15]. Multiple tumours at the first clinical
presentation are very common in the female dog
[16,17], but not in women [15]. Do these differences
indicate species-specific tumour genesis and develop-
ment? The molecular-based classification, recently
adopted for breast cancer, seems to be a better tool
than morphological features to establish objective simi-
larities between the two models. In canine mammary
tumours, the loss of hormone receptors in tumour pro-
gression is known [18,19], as is the overexpression of
ERB-B2 products in malignancies [20,21]. However, to
our knowledge, only one recent investigation merged
these two features to devise a molecular-based sub-
grouping of malignant tumours [22]. This study applied
the molecular classification to a series of canine mam-
mary carcinomas, using a panel of antibodies apt to
demonstrate a role in prognosis and identification of
molecular groups similar to human breast cancer.
The present study aimed to apply an immunohisto-
chemical panel (anti-ER, -PR, -ERB-B2, -CK 5/6 and
-CK14) in a series of canine malignant mammary
tumours to verify the molecular-based classification, its
correlation with invasion and grade, and its use as a
prognostic aid in veterinary practice.
Methods
Cases and follow-up data
Forty-five tissue samples were obtained from female
dogs with malignant primary mammary tumours. All
the dogs underwent surgery at the University Clinic of
Veterinary Surgery (Bologna, Italy) and in private clinics.
The tissue samples were immediately fixed in 10% buf-
fered formalin and routinely processed. Before surgery
and every 2 mo over a 2-yr period, radiographs of the
thorax and ultrasonograms of the spleen, liver, and kid-
neys were obtained. None of the dogs had distant
metastases (M0) at surgery. Follow-up data were col-
lected over this period and expressed as survival time
(the time between surgery and death due to the tumour,
either spontaneous death or euthanasia). After 24 mo of
follow-up, the animals still alive were considered
assessed and those that had died non-assessed.
Tumour grade and invasion
Histologic diagnoses were achieved on hematoxylin and
eosin stained slides according to Misdorp et al. [13], and
tumour grade according to Lagadic and Estrada [23].
Invasiveness (stage) was determined following a pre-
viously proposed system [24]: stage 0 = tumours without
stromal invasion (in situ); stage I = tumours with stro-
mal invasion; and stage II = tumours with neoplastic
emboli in vessels.
Immunohistochemistry
For each tumour, five 4-micron-thick consecutive sections
were used for anti-ER, -PR, -ERB-B2, -CK5/6 and -CK14
antibodies. Sections were dewaxed in toluene and rehy-
drated. Endogenous peroxidase was blocked by immersion
in 0.3% hydrogen peroxide for 20 min. Sections were then
rinsed in Tris Buffer and antigen was retrieved with citrate
buffer (2.1 g citric acid monohydrate/litre distilled water),
pH 6.0, and heating for two 5 min periods in a microwave
oven at 750 W, followed by cooling at room temperature
for 20 min. The primary antibodies are summarized in
Table 1. All antibodies were incubated with the tissue sec-
tions overnight at 4°C, except for anti-PR incubated 1.5
hours at 37°C, and were followed by a commercial strep-
toavidin-biotin-peroxidase technique (LSAB Kit, Dako,
Figure 1 Classification flowchart followed in the present study
(from Conforti et al. [7] modified).
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Page 2 of 9Amsterdam, The Netherlands). Diaminobenzidine (0.05%
for 10 min at room temperature) was used as chromogen.
Slides were counterstained with Papanicolaou’sh e m a t o x y -
lin. Negative controls were obtained substituting the pri-
mary antibody with an unrelated monoclonal antibody of
the same isotype. As positive controls to assess the cross-
reactivity with canine tissues and the specificity of the
immunohistochemical stain, sections of canine normal
mammary gland (anti-ER, -PR and -CK14 antibodies),
canine skin (anti-CK5/6) and bovine pancreas (anti-ERB-
B2 antibody) were used following the same protocols.
Interpretation of immunohistochemical staining
Staining data were classified semiquantitatively. All
immunohistochemical markers were accessed as nega-
tive and positive groups. Specifically, negative cases were
those that displayed no staining or staining in less than
a certain percentage of positive tumour cells, and posi-
tive cases were those with unequivocal staining in at
least a certain percentage of tumour cells. Positivity for
CK5/6 and CK14, according to Kim et al. [9] was
defined as the detection of at least 1% of invasive
tumour cells showing strong cytoplasmic staining.
Immunostaining for ERB-B2 was interpreted as positive
when at least 10% tumour cells showed moderate to
strong complete membranous staining [25]. Cases were
considered positive for ER or PR when nuclear staining
was observed in at least 5% tumour cells [19].
Grouping molecular subtypes
Based on a modified classification of Yang et al. [10],
tumour subtypes were defined as luminal-like A (ER+
and/or PR+, ERB-B2 -, any CK5/6 or CK14), luminal-
like B (ER+ and/or PR+, ERB-B2 +, any CK5/6 or
CK14); ERB-B2-expressing (ER-, PR-, ERB-B2 +, any
CK5/6 or CK14); basal-like (ER- and PR-, ERB-B2 -,
CK5/6 + and/or CK14+), and unclassified or normal-like
(negative for all markers).
Statistical analysis
Pearson chi-squared statistic was used to test the asso-
ciation of the molecular subtypes with numerosity of
cases homogeneous for invasion (0, I, II), grade (1, 2, 3)
and histotype group. Histotype grouping was as follows:
1) simple: including all the simple carcinomas; 2)
complex/mixed: comprising all the complex carcinomas
and carcinomas in mixed tumours; 3) others: including
the other histological types considered in the Misdorp
et al. [13] classification system. Kaplan-Meier survival
curves were calculated. To test the influence of molecu-
lar-based subgrouping (luminal-like A vs luminal-like B
vs basal-like), stage (0 vs I vs II) and grade (1 vs 2 vs 3
separately for cases with and without vascular invasion)
on survival, comparisons were verified by logrank test
corrected for multiple comparisons. To investigate the
simultaneous influence on survival, variables such as
molecular-based subgrouping (luminal-like A vs lumi-
nal-like B vs basal-like), stage (0 vs I vs II), grade (1 vs 2
vs 3) and histotype (simple vs complex/mixed) were also
examined by multivariate regression with the propor-
tional hazard Cox regression model for censored data.
Analyses were performed by CSS software (Statsoft,
Tulsa, OK) statistics, and a conventional 5% level was
used to define statistical significance.
Results
The 45 female dogs ranged from four to 15 years of age
(mean ± standard deviation = 9.66 ± 2.36; median = 10).
Twenty-seven were crossbred and 17 purebred, namely
six German shepherds, five Yorkshire terriers, two poin-
ters, two dachshunds, two poodles. For one remaining
case breed and age were not known.
Histologic diagnoses included seven in situ carcino-
mas, 19 simple carcinomas (11 tubulo-papillary and six
solid types), 25 complex/mixed carcinomas (16 complex
tubulo-papillary type and four carcinomas in mixed
tumours) and one squamous carcinoma (included in the
“other” group). Staging comprised seven non-infiltrating
tumours (in situ carcinomas, stage 0 i.e. the same identi-
fied by the morphological classification system), 24 car-
cinomas with stromal invasion (stage I), and 14
carcinomas with vascular emboli and/or regional lymph
node involvement (stage II). Grade assessment revealed
18 grade 1 (16 without and two with vascular invasion),
14 grade 2 (11 without and three with vascular invasion)
a n d1 3g r a d e3( f o u rw i t h o u ta n dn i n ew i t hv a s c u l a r
invasion) tumours. At 24 months after mastectomy, 33
of 45 cases were still alive and 12 cases had died, either
euthanized or spontaneously, in both cases due to
tumour spread.
Table 1 Primary antibodies used for immunohistochemistry in the current study.
Antibody (anti-) Clone Manufacturer Working concentration
Oestrogen Receptor polyclonal Zymed (South San Francisco, Ca) 1:50
Progesterone Receptor monoclonal PR 4-12 EMD Biosciences (San Diego, Ca) 1:10
ERB-B2 polyclonal Dako (Glostrup, Denmark) 1:50
Cytokeratin 14 monoclonal Ab-1 (LL002) NeoMarkers (Fremont, Ca) 1:300
Cytokeratins 5/6 monoclonal D5/16B4 Zymed (South San Francisco, Ca) 1:100
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PR positive whereas ten were negative; 22 cases were
classified positive to ERB-B2 and ten positive for basal
cytokeratin expression.
According to the criteria adopted for molecular sub-
type grouping, luminal B cases (n = 22 cases) accounted
for 49% of the tumours, followed by luminal A (n = 13,
29%), and basal-like (n = 10, 22%). No case was ERB-B2
expressing and no case was unassessed. Immunohisto-
chemical expression of the panel of antibodies in the
different subtypes is reported in figure 2.
No difference was present in the percentage of mole-
cular subtypes among the three invasion groups (Pear-
son Chi-square P = 0.76). A higher percentage of
luminal A and basal cases was recorded among grade 1
carcinomas (luminal A 50%, luminal B 12%, basal 38%).
The percentage of luminal B cases was higher in grade 2
(luminal A 14%, luminal B 63%, basal 23%) and grade 3
(luminal A 15%, luminal B 77%, basal 8%) carcinomas
(Pearson Chi-square P = 0.009). No difference was
found in the percentage of molecular subtypes between
simple and complex/mixed carcinomas (Pearson Chi-
square P = 0.47). The group indicated as “others” was
not investigated because of the paucity of cases (one
squamous carcinoma). These results are summarized in
table 2.
Luminal-like A, luminal-like B and basal-like groups
revealed no difference by survival analysis (P = 0.85),
but basal-like tumours showed a better outcome than
the luminal groups, and luminal B group had a slightly
worse outcome than luminal A cases (figure 3A). Inva-
sion (P = 0.0025, figure 3B) and grade, separately for
tumours with (P = 0.047, figure 3C) and without (P =
0.03, figure 3D) vascular invasion, were significantly
associated with prognosis.
Stage and grade showed independent associations with
survival in the multivariate regression (table 3), while
molecular subtype grouping and histological type did
not show associations.
Discussion
Human breast cancer is considered a heterogeneous dis-
ease according to oestrogen receptor, tumour grade and
age [26]. Studies examining comprehensive gene-expres-
sion patterns using hierarchical clustering disclosed four
clusters and suggested a four-way classification of breast
cancer: luminal-like (subsequently sub-classified as A
and B types), basal-like, HER-positive and normal-like
[1,3]. The main goal of applying this innovative classifi-
cation system is to demonstrate its role in prognosis. In
addition, this molecular-based classification of breast
cancers provides an opportunity to investigate biological
questions in homogeneous entities, and to enrich a spe-
cific subclass with a relevant signal. This might prove
superior to studies in a “diluted” population enrolling
breast cancer patients without distinction [27].
However, molecular-based sub-grouping according to
gene expression profile is impractical in laboratories
equipped for routine diagnostic tests, and provides an
imprecise picture of the actual sub-classes [27] because
mRNA levels do not always correspond to changes in
protein expression [9]. The protein quality depends not
only on the amount and rate of transcription and trans-
lation, but also on degradation and rate of transport
from cells. In addition, tissues used for mRNA profiling
include both tumour and stromal cells. Therefore,
immunohistochemistry may be beneficial in identifying
the status of cellular expression and specific location of
the protein [9]. Immunohistochemical-based markers
have been proposed to help identify the molecular cate-
gories and define these sub-classes [9,10,7,8].
In veterinary medicine, mammary gland tumours are
classified morphologically providing good prognostic
indications [28,29] that may be enhanced by further
prognostic tools such as staging [24], histological grade
[23], proliferation indexes [30,31], hormone receptor sta-
tus [19,32] and adhesion molecules expression [33,34].
However, canine malignancies form a heterogeneous
group of different molecular driven tumours which may
benefit from a classification that takes such molecular
differences into account.
The present study applied a panel of antibodies com-
monly used to characterize the molecular groups in
human pathology, and identified three tumour groups
(luminal-like A and B and basal-like) out of the five
known groups (no ERB-B2 or normal-like cases were
present in our study, due to either the paucity of cases
or to the epidemiological situation). Gama et al. [34], in
a series of 102 canine mammary carcinomas, identified
four tumour groups (luminal-like A and B, basal-like,
and HER2 overexpressing). Investigations in veterinary
medicine seem to confirm the importance of a molecu-
lar characterization of canine mammary tumours, but
further work is necessary to confirm the data from the
present study and that of Gama et al. [34].
Our study showed that the molecular-based classifica-
tion of canine mammary cancer was related to grade,
but not to invasion and morphologic classification.
Luminal-like A group tumours included a significantly
higher percentage of grade 1 tumours than luminal-like
B group in which grades 2 and 3 cancers prevailed.
Gama et al. [34] found that only the basal-like tumour
group was associated with grade and the presence of
vascular invasion. The molecular-based subgrouping of
human breast cancer was associated with histological
grade results in several investigations [10,9,7]. Simple or
complex/mixed patterns do not seem to be correlated to
a specific molecular group in our study, whereas Gama
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Page 4 of 9Figure 2 Immunohistochemical expression of the panel of antibodies applied by IHC in canine mammary carcinoma. a-c PR staining; d-
f ER staining; g-i ERB-B2 staining;j-l CK 14 staining; m-o CK 5/6 staining. Each column refers to a distinct molecular subtype. From left to right,
each column represents luminal A, luminal B and basal subtypes. 400×.
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nal-like A tumours, and simple pattern and carcinosar-
comas to HER2 overexpressing and basal-like groups.
Application of this classification system in human
medicine has yielded conflicting results on the relation
with different clinico-pathological variables and survival
where only the ERB-B2 overexpressing [9] or only the
basal-like [2] tumours showed evidence of a significantly
shorter survival. Our investigation failed to disclose any
association between the molecular-based classification
system and survival, whereas Gama et al. [34] found
only the basal-like group significantly associated with a
short survival. The difference between these studies can
be explained by the different panels and criteria adopted
to define the positivity to basal markers (cytokeratin 5/6
and 14 used in our study, and cytokeratin 5, p63 and P-
cadherin in Gama et al.’s [34] study).
Stage and grade showed independent associations with
survival in the multivariate regression (table 3), while
molecular subtype grouping and histological type did
not show associations. These data suggest that, at the
moment, caution should be used when applying this
classification system to the dog, in which the most use-
ful information for prognosis is obtained from invasion
Table 2 Pearson Chi squared statistic.
Luminal-like A
(n. 13)
Luminal-like B
(n. 22)
Basal-like
(n.10)
P value
Invasion (stage) 0.76
Non-infiltrating (0) 1 4 2
Stromal invasion (I) 8 10 6
Vascular invasion (II) 4 8 2
Grade 0.009
Grade 1 9 3 6
Grade 2 2 9 3
Grade 3 2 10 1
Histotype 0.47
Simple 6 10 3
Complex/mixed 6 12 7
Other 1 0 0
Comparison between molecular phenotypes (luminal-like A, B, and basal-like) and invasion or grade or histotype groups.
Figure 3 Kaplan-Meier overall survival curves of the different molecular (A), stage (B) and grade groups. The grade curves are presented
separately for cases with (C) or without (D) vascular invasion.
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taneous model of human breast cancer, similar tumour
types should be compared between the two species.
Because the morphological basis does not guarantee the
grouping of biologically homogeneous tumours, applica-
tion of a molecular-based system would improve the
comparison of homogeneous groups. This study and
that of Gama et al. [34] have demonstrated the existence
of molecular-categorized groups, but the similarities
between women and canine groups await confirmation
in future investigations.
Application of the molecular-based classification sys-
tem provides additional information on the different cell
origin of basal-like and luminal-like tumours. Perou et
al. [1] showed that basal-like tumours share some mole-
cular features with myoepithelial cells which constitute
the basal part of the normal epithelium, whereas lumi-
nal-like tumours have molecular features in common
with normal luminal cells. In veterinary medicine the
origin of the mesenchymal components in the so-called
complex and mixed pattern of mammary tumours is
still a matter of debate, and the myoepithelial cell is the
most probable origin [35]. In our cases the basal-like
group shared some characteristics with luminal-like A
tumours (high percentage of grade 1) that are not
known in human cancer and also conflict with the find-
ings of Gama et al. [34]. This discrepancy may have two
explanations. Firstly, the panel of antibodies and the cri-
teria adopted to identify the positivity to basal differed
in the two studies. It is known that characterization of
the basal-like group is more difficult than that of HER2-
overexpressing and luminal-like tumours, and for this
reason several different panels and score methods have
been proposed [36,37,9]. A second explanation is that
some of our basal-like cases could be luminal-like
tumours that were negative for ER and PR, but had
positive myoepithelial cells that, in canine mammary
tumours, are frequently expressed in the complex and
mixed patterns. The criterion we adopted was at least
1% of cells positive to the basal markers in the invasive
component, by virtue of the common myoepithelial pro-
liferations that would induce a high number of false
positive cases.
It is assumed that cytokeratin 5 is more sensitive than
cytokeratin 14 as a basal marker because cytokeratin 5
could be expressed by bipotential progenitor cells as
well as basal-like cells, whereas expression of cytokeratin
14 is limited to mature (basal) myoepithelial cells [9,36].
To better characterize the basal-like tumours and to
avoid confusion with cases belonging to other groups, a
panel of antibodies raised to several basal markers
should be applied in canine mammary carcinomas.
Conclusion
Application of a panel of antibodies, commonly used to
characterize the molecular groups in human pathology
disclosed three tumour groups (luminal-like A and B and
basal-like) out of the five known (no ERB-B2 or normal-
like cases were present in our samples). This finding
strengthens the assumption that canine mammary
tumours are a model of human breast cancer, but to
make this comparison more reliable, homogeneous
groups should be identified and compared. Canine malig-
nant tumours appear to be a heterogeneous group of dif-
ferent molecular driven tumours which would benefit
from a classification addressing molecular differences as
in human medicine. However, the existence in the dog of
all the groups proposed for human breast cancer and
their diversity in biological behaviour await confirmation.
Stage and grade showed independent associations with
survival in the multivariate regression, while molecular
subtype grouping and histological type did not show
associations. These data suggest that, at the moment,
caution should be used when applying this classification
system to the dog, in which the most useful information
for prognosis is obtained from invasion and grade.
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